Login to Your Account

Mesoblast's Stem Cell Therapy Works in Phase II HF Trial

By Nuala Moran
BioWorld International Correspondent

Wednesday, November 16, 2011
LONDON – Mesoblast Ltd. has revived hopes for the potential use of stem cells to treat heart disease, delivering positive results in a 60-patient Phase II trial of Revascor in congestive heart failure, and significantly for the allogeneic cell therapy, reporting the product did not provoke any adverse immune responses.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription